Science

Rahul Banerjee: CEPHEUS by Saad Z. Usmani, et al is out

Rahul Banerjee and Saad Z. Usmani

Feb 7, 2025, 08:39

Rahul Banerjee: CEPHEUS by Saad Z. Usmani, et al is out

Rahul Banerjee, Assistant professor at Fred Hutchinson Cancer Center at the University of Washington, shared an article by Saad Z. Usmani, et al. on X:

“CEPHEUS out!

Congratulations Saad Z. Usmani, et al.

PFS with quad in ASCT MMsm. Nice discussion of similarities (many) & differences (few) vs IMROZ.

CD38-VRd now the norm for many: time to shift algorithms to quad-eligible vs not regardless of ASCT plans!”

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS study.

Authors: Saad Z. Usmani, et al.

Rahul Banerjee: CEPHEUS by Saad Z. Usmani, et al is out

Bortezomib cancer CD38-VR CEPHEUS Daratumumab dexamethasone fight against cancer Fred Hutchinson Cancer Center Global fight against cancer IMROZ Lenalidomide multiple myeloma OncoDaily Oncology Rahul Banerjee Saad Z. Usmani University of Washington

April is Head and Neck Cancer Awareness Month

Is Cancer Hereditary? Myths and Facts about Cancer Genetics

Neuroendocrine Lung Tumors: Types, Symptoms, Diagnosis, Treatment and 2025 updates

Cancer Center Near Me: Dana-Farber Cancer Institute

FDA Approves Nivolumab and Ipilimumab for First-Line Treatment of Unresectable Hepatocellular Carcinoma Based on CheckMate-9DW Trial